Table 2.

Risk of colorectal cancer and antidiabetic drug use in diabetic cases and controls

Drugs and no. prescriptionsCases (%; n = 920)Controls (%; n = 5,519)Crude OR (95% CI)Adjusted ORa (95% CI)
Metformin
 No prior use504 (54.8)3,165 (57.3)1.00 (referent)1.00 (referent)
 1–9111 (12.1)665 (12.1)1.06 (0.84–1.32)1.05 (0.83–1.33)
 10–29126 (13.6)763 (13.8)1.05 (0.85–1.30)1.05 (0.84–1.33)
 30–4979 (8.6)430 (7.8)1.17 (0.90–1.52)1.17 (0.88–1.55)
 ≥50100 (10.9)496 (9.0)1.29 (1.01–1.65)1.43 (1.08–1.90)
Sulfonylureas
 No prior use462 (50.2)2,783 (50.4)1.00 (referent)1.00 (referent)
 1–994 (10.2)540 (9.8)1.05 (0.83–1.34)1.01 (0.79–1.30)
 10–29143 (15.6)884 (16.0)0.98 (0.79–1.20)0.92 (0.74–1.14)
 30–49104 (11.3)559 (10.1)1.12 (0.89–1.42)1.05 (0.81–1.35)
 ≥50117 (12.7)753 (13.7)0.93 (0.74–1.17)0.79 (0.60–1.03)
Insulin
 No prior use776 (84.3)4,583 (83.1)1.00 (referent)1.00 (referent)
 1–932 (3.5)173 (3.1)1.09 (0.74–1.60)1.11 (0.75–1.64)
 10–2931 (3.4)277 (5.0)0.66 (0.45–0.96)0.64 (0.44–0.95)
 30–4936 (3.9)198 (3.6)1.07 (0.74–1.54)1.07 (0.73–1.57)
 ≥5045 (4.9)288 (5.2)0.92 (0.66–1.28)0.90 (0.63–1.28)
  • aAdjusted for each other, BMI, smoking, diabetes duration, prior use of aspirin, NSAID, and statins.